Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3305677 in type 2 diabetes
NCT03928379Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing LY3305677 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug at 24 weeks. Started Oct 2019; status: completed.
02
Drugs
mazdutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03928379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928379.